Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cholangiocarcinoma × Taxes × Clear all

Phase

Phase 2 5 Phase 1 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Inflammatory Breast Neoplasms 1 Fallopian Tube Neoplasms 1 Epstein-Barr Virus Infections 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Carcinoma In Situ 1 Biliary Tract Neoplasms 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 4 Cisplatin 4 pembrolizumab 2 Photochemotherapy 2 futibatinib 1 Taxes 1 Radiofrequency Ablation 1 Paclitaxel 1 Neoadjuvant Therapy 1 Lasers 1 Fulvestrant 1 Drug Therapy 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 1-phenyl-3,3-dimethyltriazene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06037980 2025-02-17

PURITY

Gruppo Oncologico del Nord-Ovest

Phase 2/3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡